Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach

P, Jaismy Jacob, Manju, S.L., Ethiraj, K.R., Elias, Geetha·2018·European Journal of Pharmaceutical Sciences

Abstract

&NA; Inflammatory mediators of the arachidonic acid cascade from cyclooxygenase (COX) and lipoxygenase (LOX) pathways are primarily responsible for many diseases in human beings. Chronic inflammation is associated with the pathogenesis and progression of cancer, arthritis, autoimmune, cardiovascular and neurological diseases. Traditional non‐steroidal anti‐inflammatory agents (tNSAIDs) inhibit cyclooxygenase pathway non‐selectively and produce gastric mucosal damage due to COX‐1 inhibition and allergic reactions and bronchospasm resulting from increased leukotriene levels. ‘Coxibs’ which are selective COX‐2 inhibitors cause adverse cardiovascular events. Inhibition of any of these biosynthetic pathways could switch the metabolism to the other, which can lead to fatal side effects. Hence, there is undoubtedly an urgent need for new anti‐inflammatory agents having dual mechanism that prevent release of both prostaglandins and leukotrienes. Though several molecules have been synthesized with this objective, their unfavourable toxicity profile prevented them from being used in clinics. Here, this integrative review attempts to identify the promising pharmacophore that serves as dual inhibitors of COX‐2/5‐LOX enzymes with improved safety profile. A better acquaintance of structural features that balance safety and efficacy of dual inhibitors would be a different approach to the process of understanding and interpreting the designing of novel anti‐inflammatory agents. Graphical abstract Figure. No caption available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejps.2018.06.003

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 182

Metadata

Authors
P, J. J., Manju, S. L., Ethiraj, K. R., & Elias, G.
Venue
European Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2018-08
Volume
121
Pages
356-381
ISSN
0928-0987 (ISSN-L)
OpenAlex
W2807090014
Cited by
182
References
5
FWCI
9.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach. https://app.cochat.ai/papers/10.1016/j.ejps.2018.06.003
The paper
P, J. J., Manju, S. L., Ethiraj, K. R., & Elias, G. (2018). Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2018.06.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.